Biomarker-driven clinical trials evaluate targeted therapies and combination regimens in specific subgroups of HER2-positive breast cancer patients, such as those with HER2 mutations or amplifications, hormone receptor positivity, or specific genomic alterations. The gene discussed is ERBB2; the disease is breast cancer.